chr9-17161529-G-T
Variant names: 
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_017738.4(CNTLN):c.449+18153G>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.182 in 152,096 control chromosomes in the GnomAD database, including 2,600 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
 Genomes: 𝑓 0.18   (  2600   hom.,  cov: 32) 
Consequence
 CNTLN
NM_017738.4 intron
NM_017738.4 intron
Scores
 2
Clinical Significance
 Not reported in ClinVar 
Conservation
 PhyloP100:  0.0570  
Publications
5 publications found 
Genes affected
 CNTLN  (HGNC:23432):  (centlein) Enables protein domain specific binding activity; protein kinase binding activity; and protein-macromolecule adaptor activity. Involved in centriole-centriole cohesion and protein localization to organelle. Located in cytosol; microtubule organizing center; and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2022] 
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.81). 
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.272  is higher than 0.05. 
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt | 
|---|---|---|---|---|---|---|---|---|---|---|
| CNTLN | ENST00000380647.8 | c.449+18153G>T | intron_variant | Intron 2 of 25 | 1 | NM_017738.4 | ENSP00000370021.3 | |||
| CNTLN | ENST00000380641.4 | c.449+18153G>T | intron_variant | Intron 2 of 6 | 2 | ENSP00000370015.3 | ||||
| CNTLN | ENST00000484374.1 | n.534-5289G>T | intron_variant | Intron 2 of 2 | 2 | 
Frequencies
GnomAD3 genomes  0.182  AC: 27686AN: 151976Hom.:  2599  Cov.: 32 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
27686
AN: 
151976
Hom.: 
Cov.: 
32
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome  0.182  AC: 27690AN: 152096Hom.:  2600  Cov.: 32 AF XY:  0.183  AC XY: 13619AN XY: 74372 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
27690
AN: 
152096
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
13619
AN XY: 
74372
show subpopulations 
African (AFR) 
 AF: 
AC: 
8975
AN: 
41506
American (AMR) 
 AF: 
AC: 
3034
AN: 
15274
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
635
AN: 
3470
East Asian (EAS) 
 AF: 
AC: 
990
AN: 
5178
South Asian (SAS) 
 AF: 
AC: 
1372
AN: 
4814
European-Finnish (FIN) 
 AF: 
AC: 
1561
AN: 
10564
Middle Eastern (MID) 
 AF: 
AC: 
66
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
10582
AN: 
67972
Other (OTH) 
 AF: 
AC: 
373
AN: 
2112
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.503 
Heterozygous variant carriers
 0 
 1174 
 2348 
 3521 
 4695 
 5869 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
 0 
 306 
 612 
 918 
 1224 
 1530 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
820
AN: 
3474
ClinVar
Not reported inComputational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.